Ionis Pharmaceuticals (LTS:0JDI) Cyclically Adjusted Revenue per Share: $6.05 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JDI Ionis Pharmaceuticals Inc LTS:0JDI
71 GF Score
Price $54.81
GF Value $53.72
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Cyclically Adjusted Revenue per Share?

Ionis Pharmaceuticals LTS:0JDI -0.92% 71 Cyclically Adjusted Revenue per Share is $6.05 as of Mar. 2026. GuruFocus rates LTS:0JDI with a GF Score™ of 71/100 and a GF Value™ of $53.72 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ionis Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was $1.493. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $6.05 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ionis Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 9.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 17.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Ionis Pharmaceuticals was 23.20% per year. The lowest was -5.50% per year. And the median was 6.65% per year.

As of today (2026-07-16), Ionis Pharmaceuticals's current stock price is $54.8136. Ionis Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $6.05. Ionis Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 9.06.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ionis Pharmaceuticals was 38.42. The lowest was 4.90. And the median was 13.12.


Ionis Pharmaceuticals  (LTS:0JDI) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ionis Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=54.8136/6.05
=9.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ionis Pharmaceuticals was 38.42. The lowest was 4.90. And the median was 13.12.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ionis Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Ionis Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.20 4.43 5.01 5.45 5.87

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.48 5.73 5.71 5.87 6.05

LTS:0JDI vs EXEL, BBIO, AXSM: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


LTS:0JDI
71GF Score
Ionis Pharmaceuticals Inc LTS:0JDI
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ionis Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.493/330.2130*330.2130
=1.493

Current CPI (Mar. 2026) = 330.2130.

Ionis Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.318 241.018 0.436
201609 0.899 241.428 1.230
201612 1.537 241.432 2.102
201703 0.927 243.801 1.256
201706 0.906 244.955 1.221
201709 0.951 246.819 1.272
201712 1.323 246.524 1.772
201803 1.152 249.554 1.524
201806 0.915 251.989 1.199
201809 1.059 252.439 1.385
201812 1.328 251.233 1.745
201903 2.100 254.202 2.728
201906 1.168 256.143 1.506
201909 1.171 256.759 1.506
201912 2.680 256.974 3.444
202003 0.957 258.115 1.224
202006 1.044 257.797 1.337
202009 1.146 260.280 1.454
202012 2.074 260.474 2.629
202103 0.793 264.877 0.989
202106 0.892 271.696 1.084
202109 0.943 274.310 1.135
202112 3.116 278.802 3.691
202203 1.002 287.504 1.151
202206 0.944 296.311 1.052
202209 1.126 296.808 1.253
202212 1.069 296.797 1.189
202303 0.914 301.836 1.000
202306 1.317 305.109 1.425
202309 1.006 307.789 1.079
202312 2.260 306.746 2.433
202403 0.821 312.332 0.868
202406 1.543 314.175 1.622
202409 0.901 315.301 0.944
202412 1.435 315.605 1.501
202503 0.829 319.799 0.856
202506 2.479 322.561 2.538
202509 0.981 324.800 0.997
202512 1.252 324.054 1.276
202603 1.493 330.213 1.493

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $6.05 mean?
Ionis Pharmaceuticals (LTS:0JDI) has a Cyclically Adjusted Revenue per Share of $6.05 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Ionis Pharmaceuticals' current Cyclically Adjusted Revenue per Share is $6.05. Overall, Ionis Pharmaceuticals has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to EXEL and BBIO?
Ionis Pharmaceuticals' Cyclically Adjusted Revenue per Share of $6.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Cyclically Adjusted Revenue per Share is $6.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (LTS:0JDI) is currently considered Fairly Valued. The stock's GF Value™ is $53.72, compared to a current price of $54.81 — trading 2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $6.05. Ionis Pharmaceuticals' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ionis Pharmaceuticals (LTS:0JDI), the current Cyclically Adjusted Revenue per Share is $6.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (LTS:0JDI) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of $54.81 is trading 2% above its estimated GF Value™ of $53.72. GuruFocus considers Ionis Pharmaceuticals to be Fairly Valued.

Key valuation signals for LTS:0JDI:

  • Cyclically Adjusted Revenue per Share: $6.05
  • GF Value™: $53.72 vs. price of $54.81 (2% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the LTS:0JDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
71GF Score

Get the complete analysis for LTS:0JDI

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.81
Price
$53.72
GF Value